BIOGEN INC. - COMMON S

Update on Regulatory Review of Aducanumab in the European Union

17 Nov 2021 07:30:00 By Nasdaq GlobeNewswire

The European Commission Grants Marketing Authorization for VUMERITY® (diroximel fumarate) as Oral Treatment for Relapsing-Remitting Multiple Sclerosis

16 Nov 2021 09:20:00 By Nasdaq GlobeNewswire

Biogen Announces Alfred W. Sandrock, Jr. to Retire as Head of Research & Development

15 Nov 2021 19:44:06 By Nasdaq GlobeNewswire

Biogen Sets Industry Record with Recognition on Dow Jones Sustainability World Index for 9th Consecutive Year

15 Nov 2021 07:30:01 By Nasdaq GlobeNewswire

New Phase 3 Data Show Positive Correlation Between ADUHELM™ Treatment Effect on Biomarkers and Reduction in Clinical Decline in Alzheimer’s Disease

11 Nov 2021 17:10:00 By Nasdaq GlobeNewswire

Biogen Announces Late Breakers and Additional New Data Presentations at the 2021 Clinical Trials on Alzheimer’s Disease (CTAD) Meeting

03 Nov 2021 07:30:01 By Nasdaq GlobeNewswire

Biogen Announces Topline Results from the Tofersen Phase 3 Study and its Open-Label Extension in SOD1-ALS

17 Oct 2021 16:20:00 By Nasdaq GlobeNewswire

Topline Results from Tofersen Phase 3 Study and its Open Label Extension in SOD1-ALS to be Presented at the American Neurological Association Annual Meeting

14 Oct 2021 16:06:00 By Nasdaq GlobeNewswire

New Data at ECTRIMS 2021 Highlight Biogen’s Focus on Patient-Centered Outcomes and Improving the MS Patient Experience

13 Oct 2021 06:05:00 By Nasdaq GlobeNewswire

New MS PATHS Data at ECTRIMS 2021 Confirm Biogen’s Disease-Modifying Therapies Do Not Reduce Antibody Response to COVID-19 Vaccines in People with Multiple Sclerosis

13 Oct 2021 06:02:00 By Nasdaq GlobeNewswire